{"id":32376,"date":"2017-08-01T12:01:08","date_gmt":"2017-08-01T12:01:08","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=32376"},"modified":"2017-08-14T13:19:31","modified_gmt":"2017-08-14T13:19:31","slug":"fda-approves-sofosbuvirvelpatasvirvoxilaprevir-vosevi-second-line-daa-hcv-treatment-in-the-us-in-the-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/32376","title":{"rendered":"FDA approves sofosbuvir\/velpatasvir\/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 18 July 2017, the US FDA approved a fixed dose combination of sofosbuvir\/velpatasvir\/voxilaprevir (400\/100\/100) for treatment of DAA-experienced adults with chronic hepatitis C (HCV).<\/strong><\/p>\n<p>The indication is for adults with genotype 1, 2, 3, 4, 5 or 6 with unsuccessful treatment using an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.<\/p>\n<p>Approval is based on results from the phase 3 POLARIS-1 and POLARIS-4 studies, which used 12 weeks of Vosevi in direct-acting antiviral-experienced chronic HCV-infected patients without cirrhosis or with compensated cirrhosis.<\/p>\n<p>Sofosbuvir\/velpatasvir\/voxilaprevir is manufactured by Gilead Sciences and marketed with the brandname Vosevi.<\/p>\n<p>Reference:<\/p>\n<p>Gilead press statement. US Food and Drug Administration approves Gilead\u2019s Vosevi (sofosbuvir\/velpatasvir\/voxilaprevir) for re-treatment of adults with chronic hepatitis C virus. (18 July 2017).<br \/>\n<a href=\"http:\/\/www.gilead.com\/news\/press-releases\">http:\/\/www.gilead.com\/news\/press-releases<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 18 July 2017, the US FDA approved a fixed dose combination of sofosbuvir\/velpatasvir\/voxilaprevir (400\/100\/100) for treatment of DAA-experienced adults with chronic hepatitis C (HCV). The indication is for adults with genotype 1, 2, 3, 4, &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-32376","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=32376"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32376\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=32376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=32376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=32376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}